Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice.

Moya IM, Castaldo SA, Van den Mooter L, Soheily S, Sansores-Garcia L, Jacobs J, Mannaerts I, Xie J, Verboven E, Hillen H, Algueró-Nadal A, Karaman R, Van Haele M, Kowalczyk W, De Waegeneer M, Verhulst S, Karras P, van Huffel L, Zender L, Marine JC, Roskams T, Johnson R, Aerts S, van Grunsven LA, Halder G.

Science. 2019 Nov 22;366(6468):1029-1034. doi: 10.1126/science.aaw9886.

PMID:
31754005
2.

Empagliflozin in type 1 diabetes.

Mathieu C, Van Den Mooter L, Eeckhout B.

Diabetes Metab Syndr Obes. 2019 Aug 22;12:1555-1561. doi: 10.2147/DMSO.S194688. eCollection 2019. Review.

3.

Efficacy of dapagliflozin as an adjunct therapy in patients with inadequately controlled type 1 diabetes mellitus.

Van den Mooter L, Caerels S, Mathieu C.

Expert Opin Pharmacother. 2018 Apr;19(6):617-622. doi: 10.1080/14656566.2018.1450387. Epub 2018 Mar 14.

PMID:
29537892
4.

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state.

Verfaillie A, Imrichova H, Atak ZK, Dewaele M, Rambow F, Hulselmans G, Christiaens V, Svetlichnyy D, Luciani F, Van den Mooter L, Claerhout S, Fiers M, Journe F, Ghanem GE, Herrmann C, Halder G, Marine JC, Aerts S.

Nat Commun. 2015 Apr 9;6:6683. doi: 10.1038/ncomms7683.

Supplemental Content

Loading ...
Support Center